Bruker launches new solution for MS imaging

Skip to Navigation


  • Published: Oct 26, 2015
  • Author: Jon Evans
  • Source: Bruker Corporation
  • Suppliers: Bruker Corporation
  • Channels: Proteomics & Genomics / Base Peak

Bruker has launched its novel Molecular Drug Imager solution for pre-clinical drug and metabolite imaging.

MALDI-based tissue imaging for pharmaceutical development is a powerful technique for localizing small molecule drugs and their metabolites, or lipids, within tissue structures, providing key insights into physiological function that were unavailable with previous technologies. With its powerful software and workflow flexibility, the new Molecular Drug Imager solution is poised to take small molecule mass spectrometry imaging (MSI) to the next level by empowering fast, accurate and thorough evaluation of drug candidates and their metabolites in model tissues and beyond.

For more than a decade, Bruker has provided industry-leading advances in hardware and methods for MALDI-based MSI. The recently introduced rapifleX MALDI-TOF system has set new standards for speed and pixel fidelity for protein imaging and molecular histology research. In addition, the solariX XR FTMS system successfully merged MALDI small molecule imaging with Isotopic Fine Structure analysis for undisputable molecular formula specificity.

The Molecular Drug Imager leverages the unparalleled power of solariX-based small molecule imaging to provide a comprehensive analysis-to-answer imaging workflow solution for pharmaceutical investigators at all levels, from biomarker discovery and validation to drug development studies. Many of the top 25 pharma companies are already using earlier versions of this MSI technology in their pre-clinical efforts to complement or replace expensive workflows, such as Quantitative Whole-Body Autoradiography, and to migrate certain animal based pre-clinical models to tissue proxies.

Providing traditional MALDI imaging analysis functions such as combining optical and molecular images, the Molecular Drug Imager in its first workflow facilitates localizing multi-generational metabolic products of drug candidates by in silico metabolism followed by automated image generation of predicted metabolites in analyzed tissues. This results in significant time savings through automation of this critical workflow, which is becoming commonplace in advanced laboratories worldwide.

The second advanced workflow provides a rapid discovery tool based on comprehensive statistical treatment of imaging datasets. Powered by the SCiLS lab software suite, powerful next-generation statistical algorithms such as PLSA and univariate and multivariate modalities can rapidly analyze imaging regions to identify unknown metabolites and biomarkers through spatial co-localization.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved